Has Helen Tergin, MD received payments from drug or device companies?

Yes. Drug and device makers reported $6,463 in general payments to Helen Tergin, MD across 347 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Helen Tergin, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Helen Tergin, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Helen Tergin, MD

Dermatology · Columbia, MONPI 1578540571

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.0% of the total across 347 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 37.8% of the total.

$6,463in general payments, 2019–2025

Across 347 payments — averaging $18.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$2K
Johnson & Johnson$942
Novartis$728
Merz North America, Inc.$654
Pfizer$391
Lilly USA, LLC$282
plus $1K from 20 others

$125,551in research payments, 2019–2025

Across 4 payments — averaging $31,388 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Amgen$106K
Pfizer$11K
Sun Pharmaceutical Industries Inc.$9K

What the payments were for

Food & beverage$6,27097%
Education$1923%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	163	$2,444
Johnson & Johnson	38	$942
Novartis	37	$728
Merz North America, Inc.	9	$654
Pfizer	25	$391
Lilly USA, LLC	14	$282
UCB, Inc.	13	$218
Amgen	5	$110
Sun Pharmaceutical Industries Inc.	7	$106
E.r. Squibb & Sons, L.L.C.	4	$94
Galderma Laboratories, L.p.	6	$83
LEO Pharma Inc.	3	$50
Aclaris Therapeutics, Inc.	3	$49
DUSA Pharmaceuticals, Inc.	2	$44
Almirall LLC	2	$39
Prugen, Inc. Pharmaceuticals	3	$35
Biofrontera Inc.	2	$32
Regeneron Healthcare Solutions, Inc.	2	$30
Genentech USA, Inc.	2	$26
Krystal Biotech Inc	1	$23
Boehringer Ingelheim	1	$17
Convatec Inc.	1	$15
EPI Health, LLC	1	$14
Ortho Dermatologics, A Division Of Bausch Health US, LLC	1	$13
Dermira, Inc.	1	$12
Bristol Myers Squibb	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

XEOMIN$373

How this compares

$6,463 in reported general payments places this provider in the 70th percentile of 263 dermatology providers in Missouri.

See all dermatology providers in Missouri →

Medicare billing

Part B allowed, 2024

$374,354

Medicare patients

1,141

Services billed

6,618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Metronidazole	28	$2,007
Ketoconazole	71	$1,412
Doxycycline Hyclate	66	$1,039
Clobetasol Propionate	24	$909
Clindamycin Phosphate	17	$673
Triamcinolone Acetonide	85	$661
Fluocinonide	12	$570
Hydrocortisone	49	$271
Mupirocin	44	$240
ValacyclovirValacyclovir Hcl	12	$232
Cephalexin	43	$137

Paid to pharmacies, not to this prescriber.

Other dermatology in Columbia

Kaitlin SchiavoColumbia$16K
Kimberly CayceColumbia$10K
Justin WelchColumbia$10K
Brian KimSaint Louis$861K
Elaine SiegfriedSaint Louis$856K
Craig LeonardiSaint Louis$569K
Jonathan CleaverKirksville$483K
Mary GeorgeSaint Louis$400K
David CleaverKirksville$371K
Christy RaineyBranson$328K

See the full list for Missouri →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →